Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 13/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 13/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18531650 | 1.00 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3HIF1AHSD17B10 | |
| SCHEMBL7897603 | 1.00 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3HIF1AHSD17B10 | |
| SCHEMBL13416392 | 0.97 | — | — | |
| SCHEMBL320423 | 0.97 | — | — | |
| SCHEMBL14038810 | 0.97 | — | — | |
| Bromide SCHEMBL11542096 | 0.95 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3HIF1AHSD17B10 | |
| SCHEMBL4762840 | 0.90 | — | — | |
| SCHEMBL1104709 | 0.90 | — | — | |
| SCHEMBL489437 | 0.90 | — | — | |
| Hydrochloric Acid SCHEMBL25314974 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023192961-A2 | LIGAND-PAYLOAD CONJUGATES | PYXIS ONCOLOGY, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20220127271-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC SHP2 INHIBITOR COMPOUND, PREPARATION METHOD, AND USE | SHANGHAI RINGENE BIOPHARMA CO., LTD. (CN) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127271-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC SHP2 INHIBITOR COMPOUND, PREPARATION METHOD, AND USE | PTPN1, PTPN7, PTPN9 | SLC6A2 4331/4885SLC6A4 4250/4885SLC6A3 4102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.